Effect of Olmesartan Medoxomil on Arterial Stiffness and Thickness in Subjects With Metabolic Syndrome.

Trial Profile

Effect of Olmesartan Medoxomil on Arterial Stiffness and Thickness in Subjects With Metabolic Syndrome.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Oct 2014

At a glance

  • Drugs Olmesartan medoxomil (Primary)
  • Indications Hypertension
  • Focus Registrational; Therapeutic Use
  • Sponsors Daiichi Sankyo Europe
  • Most Recent Events

    • 17 Jun 2013 Results presented at the 23rd European Meeting on Hypertension.
    • 03 Jul 2012 Planned number of patients changed from 318 to 350 as reported by EudraCT.
    • 03 Jul 2012 Additional trial locations (France, Netherlands) identified as reported by EudraCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top